Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) reached a new 52-week high during mid-day trading on Thursday following a stronger than expected earnings report. The stock traded as high as $14.51 and last traded at $14.47, with a volume of 4576 shares. The stock had previously closed at $13.57.
The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.05. The firm had revenue of $32.49 million during the quarter, compared to analyst estimates of $30.11 million. Deciphera Pharmaceuticals had a negative return on equity of 79.39% and a negative net margin of 231.99%. Deciphera Pharmaceuticals’s quarterly revenue was up 37.8% on a year-over-year basis. During the same period in the previous year, the company earned ($1.21) earnings per share.
Analysts Set New Price Targets
A number of brokerages have commented on DCPH. JMP Securities upgraded Deciphera Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $23.00 target price for the company in a research note on Friday. SVB Leerink boosted their target price on Deciphera Pharmaceuticals from $15.00 to $21.00 and gave the stock an “outperform” rating in a report on Friday. Finally, HC Wainwright boosted their target price on Deciphera Pharmaceuticals from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Friday. Two analysts have rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, Deciphera Pharmaceuticals has an average rating of “Hold” and a consensus price target of $14.13.
Institutional Inflows and Outflows
Deciphera Pharmaceuticals Stock Performance
The firm’s 50 day simple moving average is $12.77 and its 200-day simple moving average is $10.49.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.
- Get a free copy of the StockNews.com research report on Deciphera Pharmaceuticals (DCPH)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.